Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
AssigneeNovartis AG
InventorsCatherine Leblanc, Stephen Carl McKeown, Anett Perlberg, Nicola Tufilli
Life of this patent
Estimating the term…
Abstract
The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.
Claims9
A crystalline form of the compound:
A pharmaceutical composition comprising a crystalline form of the compound:
- and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a crystalline form of the compound:
- and a pharmaceutically acceptable carrier, which is in an inhalable dry powder form.
A method of activating prostacyclin receptor in a patient, comprising administering to said patient a therapeutically effective amount of a crystalline form of the compound:
A crystalline form of the compound:
- which has the following characteristic diffraction lines (2θ) in the X-ray diffraction pattern thereof:
- 6.8 °, 9.4° and 22.1 °.
A crystalline form of the compound:
- which has the following characteristic diffraction lines (2θ) in the X-ray diffraction pattern thereof:
- 9.3 °, 18.6° and 22.1°.
A crystalline form of the compound:
- which has the following characteristic diffraction lines (2θ) in the X-ray diffraction pattern thereof:
- 18.8°, 19.1°, 23.1° and 23.5°.
Dependencies are inferred from the claim text.